Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes-Reference-Cited by-同舟云学术

Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes

Published:2023-09 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Kasi Pashtoon Murtaza¹^ORCID,Bucheit Leslie A.²^ORCID,Liao Jiemin²^ORCID,Starr Jason³^ORCID,Barata Pedro⁴^ORCID,Klempner Samuel J.⁵^ORCID,Gandara David⁶^ORCID,Shergill Ardaman⁷,Madeira da Silva Luciana²^ORCID,Weipert Caroline²^ORCID,Zhang Nicole²,Pretz Christopher²,Hardin Aaron²^ORCID,Kiedrowski Lesli A.²^ORCID,Odegaard Justin I.²

Affiliation:

1. Weill Cornell Medicine, New York, NY

2. Guardant Health, Inc, Redwood City, CA

3. Mayo Clinic, Jacksonville, FL

4. Case Western Reserve University/University Hospitals, Cleveland, OH

5. Massachusetts General Hospital, Boston, MA

6. UC Davis Comprehensive Cancer Center, Sacramento, CA

7. University of Chicago Comprehensive Cancer Center, Chicago, IL

Abstract

MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.

Publisher

American Society of Clinical Oncology (ASCO)